Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Resumes China, India Inspections In Bid To Keep Drug Approvals On Schedule

Executive Summary

Agency’s struggle to meet user fee commitments despite travel restrictions expected to worsen as pandemic continues into 2021.

You may also be interested in...



US FDA Looks To Resume Unannounced Inspections In India And China

After lapsing due to COVID-19, an unannounced foreign inspection pilot program is on track to resume in 2022, “despite challenges and constraints of travel.”

US FDA Looks To Resume Unannounced Inspections In India And China

After lapsing due to COVID-19, an unannounced foreign inspection pilot program is on track to resume in 2022, “despite challenges and constraints of travel.”

US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds

The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS143671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel